AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24856575 — intervention group
Group type: EXPERIMENTAL
Intervention: Oblique supine lithotomy position
Number of subjects: 203
Study 24856575 — intervention group
Group type: COMPARATOR
Intervention: Prone position
Number of subjects: 203
Study 24501360 — intervention group
Group type: EXPERIMENTAL
Intervention: Active location recall
Number of subjects: 0
Study 24501360 — intervention group
Group type: COMPARATOR
Intervention: Passive dragging of objects to predetermined locations
Number of subjects: 0
Study 21630376 — intervention group
Group type: EXPERIMENTAL
Intervention: Univalent stimuli
Number of subjects: 0
Study 21630376 — intervention group
Group type: COMPARATOR
Intervention: Bivalent stimuli
Number of subjects: 0
Study 21199306 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture at Sanyinjiao (SP6)
Number of subjects: 52
Study 21199306 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture at GB39
Number of subjects: 52
Study 21199306 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture at non-meridian point
Number of subjects: 52
Study 21199306 — intervention group
Group type: COMPARATOR
Intervention: Waiting list group
Number of subjects: 52
Study 17438709 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training (Phys)
Number of subjects: 211
Study 17438709 — intervention group
Group type: EXPERIMENTAL
Intervention: Information (Info)
Number of subjects: 211
Study 17438709 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training plus information (PhysInfo)
Number of subjects: 211
Study 17438709 — intervention group
Group type: COMPARATOR
Intervention: Standard care (C)
Number of subjects: 211
Study 17438709 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Function (PF)
Number of subjects: 211
Study 17438709 — intervention group
Group type: EXPERIMENTAL
Intervention: Role Function (RF)
Number of subjects: 211
Study 17438709 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue (FA)
Number of subjects: 211
Study 16130647 — intervention group
Group type: EXPERIMENTAL
Intervention: Australian Orthotics Laboratory, three-quarter-length, flexible, shoe inserts
Number of subjects: 47
Study 16130647 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 47
Study 11854123 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 173
Study 10419910 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach educational seminar combined with on-site sigmoidoscopy services
Number of subjects: 9
Study 10419910 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no intervention)
Number of subjects: 9
Study 10419910 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention sites
Number of subjects: 9
Study 10419910 — intervention group
Group type: COMPARATOR
Intervention: Control sites
Number of subjects: 9
Study 8843936 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated telephone reminders
Number of subjects: 213
Study 8843936 — intervention group
Group type: COMPARATOR
Intervention: No reminders (control group)
Number of subjects: 213
Study 1611835 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponalrestat (600 mg day‐1)
Number of subjects: 50
Study 1611835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 6365809 — intervention group
Group type: EXPERIMENTAL
Intervention: sfericase (2 tablets, 3 times/day, total daily dose of 6 tablets)
Number of subjects: 109
Study 29332024 — intervention group
Group type: EXPERIMENTAL
Intervention: Apotel (1 g in 200 cc normal saline for 20 min)
Number of subjects: 70
Study 29332024 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil (0.5 μg/kg/min)
Number of subjects: 70
Study 29332024 — intervention group
Group type: EXPERIMENTAL
Intervention: Narcotic use
Number of subjects: 70
Study 29332024 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure and heart rate
Number of subjects: 70
Study 29378040 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast Group (≥700 kcal before 1100)
Number of subjects: 31
Study 29378040 — intervention group
Group type: COMPARATOR
Intervention: Fasting Group (0 kcal until 1200)
Number of subjects: 31
Study 29378040 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast Group
Number of subjects: 31
Study 29378040 — intervention group
Group type: COMPARATOR
Intervention: Fasting Group
Number of subjects: 31
Study 29378040 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 31
Study 27236292 — intervention group
Group type: EXPERIMENTAL
Intervention: Active low-level laser therapy (LLLT)
Number of subjects: 39
Study 27236292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 23480201 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational-behavioural skills protocol for plaque control
Number of subjects: 60
Study 23480201 — intervention group
Group type: COMPARATOR
Intervention: Basic oral hygiene instruction (Control)
Number of subjects: 60
Study 21829216 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day pre-coded food record (PFR) in 9-month-old infants
Number of subjects: 72
Study 21829216 — intervention group
Group type: COMPARATOR
Intervention: 7-day weighed food record (WFR) in 9-month-old infants
Number of subjects: 72
Study 21829216 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day pre-coded food record (PFR) in 36-month-old children
Number of subjects: 72
Study 21829216 — intervention group
Group type: COMPARATOR
Intervention: 7-day weighed food record (WFR) in 36-month-old children
Number of subjects: 72
Study 20640546 — intervention group
Group type: EXPERIMENTAL
Intervention: Power Training (PT)
Number of subjects: 0
Study 20640546 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 0
Study 20640546 — intervention group
Group type: COMPARATOR
Intervention: Power Training (PT) and Hormone Replacement Therapy (HRT)
Number of subjects: 0
Study 17324827 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene gel 0.1%
Number of subjects: 136
Study 17324827 — intervention group
Group type: COMPARATOR
Intervention: Gel vehicle
Number of subjects: 136
Study 16286743 — intervention group
Group type: EXPERIMENTAL
Intervention: Lichtena plus 25 microg/g triamcinolone acetonide (TACA)
Number of subjects: 14
Study 16286743 — intervention group
Group type: COMPARATOR
Intervention: Plain Lichtena (placebo)
Number of subjects: 14
Study 11898768 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins C and E (200mg vitamin C and 50mg vitamin E, both twice per day for 4 weeks)
Number of subjects: 117
Study 11898768 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (Bismuth chelate, tetracycline, and metronidazole for 2 weeks)
Number of subjects: 117
Study 11898768 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (Vitamins C and E + Triple therapy)
Number of subjects: 117
Study 11898768 — intervention group
Group type: COMPARATOR
Intervention: Normal controls (n=61)
Number of subjects: 117
Study 10211862 — intervention group
Group type: EXPERIMENTAL
Intervention: NordicTrack (NT) cross‐country ski simulator
Number of subjects: 28
Study 10211862 — intervention group
Group type: COMPARATOR
Intervention: Treadmill (TM) test utilizing the Bruce protocol
Number of subjects: 28
Study 7599850 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine (0.03 to 256 mg/ml)
Number of subjects: 12
Study 7599850 — intervention group
Group type: COMPARATOR
Intervention: Hypertonic saline (0.9 to 14.4% NaCl)
Number of subjects: 12
Study 1450684 — intervention group
Group type: EXPERIMENTAL
Intervention: Yeast-derived recombinant vaccine 1
Number of subjects: 3
Study 1450684 — intervention group
Group type: EXPERIMENTAL
Intervention: Yeast-derived recombinant vaccine 2
Number of subjects: 3
Study 1450684 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma-derived vaccine
Number of subjects: 3
Study 6364880 — intervention group
Group type: EXPERIMENTAL
Intervention: alcohol/onion extract (5% ethanol)
Number of subjects: 12
Study 6364880 — intervention group
Group type: COMPARATOR
Intervention: control (5% ethanol solution)
Number of subjects: 12
Study 31436165 — intervention group
Group type: EXPERIMENTAL
Intervention: mMitra, a stage-based voice messaging program
Number of subjects: 0
Study 29396000 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling of antibiotics (third-generation or fourth-generation cephalosporins, piperacillin-tazobactam, and carbapenems)
Number of subjects: 745
Study 29396000 — intervention group
Group type: COMPARATOR
Intervention: Mixing strategy (changing antibiotic to an alternative class for each consecutive patient)
Number of subjects: 745
Study 29396000 — intervention group
Group type: EXPERIMENTAL
Intervention: All-cause in-ICU mortality
Number of subjects: 745
Study 27273879 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN) - 30 kcal/kg/day, 0.16 gN/kg/day for 12 hours prior to operation
Number of subjects: 22
Study 27273879 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion for 12 hours prior to operation
Number of subjects: 22
Study 24751304 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepine users (at baseline or during follow-up)
Number of subjects: 482
Study 24751304 — intervention group
Group type: COMPARATOR
Intervention: Benzodiazepine non-users
Number of subjects: 482
Study 24751304 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who initiated benzodiazepines during follow-up
Number of subjects: 482
Study 24751304 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with comorbid anxiety or substance use disorders
Number of subjects: 482
Study 21863458 — intervention group
Group type: EXPERIMENTAL
Intervention: Centre of Pressure (CoP) measurements
Number of subjects: 97
Study 21863458 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline and 12-week follow-up CoP measurements
Number of subjects: 97
Study 20703197 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone extended-release (ER) tablets, 3-15 mg/day (9 mg starting dose)
Number of subjects: 235
Study 20703197 — intervention group
Group type: COMPARATOR
Intervention: Paliperidone extended-release (ER) tablets
Number of subjects: 235
Study 17113683 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol/acetaminophen 75 mg/650 mg
Number of subjects: 603
Study 17113683 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone/acetaminophen 7.5 mg/650 mg
Number of subjects: 603
Study 17113683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 603
Study 16292444 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro Root MTA (Dentsply) with 2% methylene blue solution
Number of subjects: 56
Study 16292444 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc oxide-eugenol cement (ZOE) with 2% methylene blue solution
Number of subjects: 56
Study 16292444 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro Root MTA (Dentsply) with 0.2% rhodamine B
Number of subjects: 56
Study 16292444 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc oxide-eugenol cement (ZOE) with 0.2% rhodamine B
Number of subjects: 56
Study 12111134 — intervention group
Group type: EXPERIMENTAL
Intervention: (131)I‐Lipiodol combined with low-dose cisplatin (30 mg/m2)
Number of subjects: 20
Study 12111134 — intervention group
Group type: COMPARATOR
Intervention: (131)I‐Lipiodol therapy alone
Number of subjects: 20
Study 12111134 — intervention group
Group type: EXPERIMENTAL
Intervention: (131)I‐Lipiodol combined with low-dose cisplatin
Number of subjects: 20
Study 12111134 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin administration
Number of subjects: 20
Study 10536065 — intervention group
Group type: EXPERIMENTAL
Intervention: Nested PCR
Number of subjects: 117
Study 10536065 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycobacterial cultures
Number of subjects: 117
Study 10536065 — intervention group
Group type: EXPERIMENTAL
Intervention: Smears
Number of subjects: 117
Study 10536065 — intervention group
Group type: COMPARATOR
Intervention: Control group (children without active disease)
Number of subjects: 117
Study 7892259 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-platelet IgG
Number of subjects: 27
Study 7892259 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-ICs
Number of subjects: 27
Study 7892259 — intervention group
Group type: EXPERIMENTAL
Intervention: F(ab')2 fragments of anti-platelet IgG
Number of subjects: 27
Study 7892259 — intervention group
Group type: EXPERIMENTAL
Intervention: Scatchard analysis
Number of subjects: 27
Study 1977779 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy
Number of subjects: 1084
Study 1977779 — intervention group
Group type: COMPARATOR
Intervention: Not taking beta-blocker
Number of subjects: 1084
Study 326380 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative procedure (mammary resection plus axillary dissection plus radiotherapy)
Number of subjects: 331
Study 326380 — intervention group
Group type: COMPARATOR
Intervention: Radical mastectomy
Number of subjects: 331
Study 31469710 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sleep deprivation after eccentric exercise‐induced muscle damage (DEPRIVATION)
Number of subjects: 10
Study 31469710 — intervention group
Group type: COMPARATOR
Intervention: Regular sleep after eccentric exercise‐induced muscle damage (SLEEP)
Number of subjects: 10
Study 31554878 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous cardiac and lung CT (Gr.A)
Number of subjects: 110
Study 31554878 — intervention group
Group type: COMPARATOR
Intervention: Standard cardiac CT only (Gr.B)
Number of subjects: 110
Study 27584910 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid for breast cancer prevention
Number of subjects: 150
Study 27584910 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 150
Study 25640536 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas, dust, and fumes (GDF) exposure
Number of subjects: 788
Study 23070934 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 78
Study 23070934 — intervention group
Group type: COMPARATOR
Intervention: Community caregiver education and support (CCES)
Number of subjects: 78
Study 20690865 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (daily tablet for 6 months)
Number of subjects: 60
Study 20690865 — intervention group
Group type: COMPARATOR
Intervention: Control (no hormone therapy)
Number of subjects: 60
Study 19075260 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg weekly
Number of subjects: 216
Study 19075260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 16420289 — intervention group
Group type: EXPERIMENTAL
Intervention: NG ‐monomethyl‐L‐arginine (L‐NMMA)
Number of subjects: 22
Study 16420289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 15313671 — intervention group
Group type: EXPERIMENTAL
Intervention: Peg-IFN alpha-2a (pegasys)
Number of subjects: 202
Study 15313671 — intervention group
Group type: COMPARATOR
Intervention: IFN-alpha-2a (roferon-A)
Number of subjects: 202
Study 15313671 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype 1 HCV
Number of subjects: 202
Study 15313671 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype non-1 HCV
Number of subjects: 202
Study 15313671 — intervention group
Group type: COMPARATOR
Intervention: Genotype 1 HCV in roferon-A group
Number of subjects: 202
Study 15313671 — intervention group
Group type: COMPARATOR
Intervention: Genotype non-1 HCV in roferon-A group
Number of subjects: 202
Study 11352878 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab (n=13)
Number of subjects: 23
Study 11352878 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=10)
Number of subjects: 23
Study 9413962 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic arterial resistance index (HARI)
Number of subjects: 31
Study 9413962 — intervention group
Group type: COMPARATOR
Intervention: Liver function tests (SGOT, SGPT, ALK, LDH, ALB)
Number of subjects: 31
Study 8280821 — intervention group
Group type: EXPERIMENTAL
Intervention: sucralfate gel (Gastrogel)
Number of subjects: 25
Study 8280821 — intervention group
Group type: COMPARATOR
Intervention: sucralfate suspension
Number of subjects: 25
Study 3449067 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of piretanide (6 mg)
Number of subjects: 10
Study 3449067 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of piretanide (6 mg)
Number of subjects: 10
Study 29635492 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic Acid (FA) supplementation (400 µg/d)
Number of subjects: 86
Study 29635492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 27490103 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavones (2 capsules of 20 mg per day) and placebo of vitamin D (P+S)
Number of subjects: 100
Study 27490103 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (50,000 IU biweekly) and placebo of soy isoflavones (D+P)
Number of subjects: 100
Study 27490103 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavones and Vitamin D (D+S)
Number of subjects: 100
Study 27490103 — intervention group
Group type: COMPARATOR
Intervention: Placebo of vitamin D and placebo of soy isoflavones (P+P)
Number of subjects: 100
Study 25406653 — intervention group
Group type: EXPERIMENTAL
Intervention: XJXGF formula
Number of subjects: 140
Study 25406653 — intervention group
Group type: COMPARATOR
Intervention: Low-dose XJXGF (10% of the XJXGF formula)
Number of subjects: 140
Study 23478617 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Karydakis flap
Number of subjects: 120
Study 23478617 — intervention group
Group type: COMPARATOR
Intervention: Modified Limberg flap
Number of subjects: 120
Study 20063254 — intervention group
Group type: EXPERIMENTAL
Intervention: Think/No‐Think task with anticipatory phase
Number of subjects: 0
Study 20063254 — intervention group
Group type: COMPARATOR
Intervention: Think/No‐Think task without anticipatory phase
Number of subjects: 0
Study 18729811 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% caloric restriction (CR)
Number of subjects: 18
Study 18729811 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% exercise (EX)
Number of subjects: 18
Study 18729811 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 18
Study 15922988 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic myomectomy by enucleation of a myoma by morcellation while it is still attached to the uterus (Group A)
Number of subjects: 44
Study 15922988 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic myomectomy by conventional technique (Group B)
Number of subjects: 44
Study 12535810 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone treatment
Number of subjects: 104
Study 12535810 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiologists' care
Number of subjects: 104
Study 12535810 — intervention group
Group type: EXPERIMENTAL
Intervention: General use of spironolactone
Number of subjects: 104
Study 12535810 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical follow-up
Number of subjects: 104
Study 10232562 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoprostenol (prostaglandin I2), 500 microg intravenous bolus before cold perfusion
Number of subjects: 106
Study 10232562 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoprostenol (prostaglandin I2)
Number of subjects: 106
Study 10232562 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 106
Study 8553333 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin, 4 mg daily
Number of subjects: 16
Study 8553333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 1704153 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline 1 g
Number of subjects: 0
Study 1704153 — intervention group
Group type: COMPARATOR
Intervention: Bleomycin 60 U
Number of subjects: 0
Study 6405939 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% acyclovir cream applied topically five times a day for five days
Number of subjects: 49
Study 6405939 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 49
Study 30897986 — intervention group
Group type: EXPERIMENTAL
Intervention: Early staples removal (postoperative day 4)
Number of subjects: 104
Study 30897986 — intervention group
Group type: COMPARATOR
Intervention: Late staples removal (postoperative day 8)
Number of subjects: 104
Study 29247235 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing into snow with an artificial air pocket at high snow density
Number of subjects: 0
Study 29247235 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing into snow with an artificial air pocket at low snow density
Number of subjects: 0
Study 27436632 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended release implantable naltrexone
Number of subjects: 306
Study 27436632 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral naltrexone
Number of subjects: 306
Study 27436632 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral and implant)
Number of subjects: 306
Study 24372302 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-irrigated radiofrequency catheter ablation (oiRFA) with saline volume administration
Number of subjects: 42
Study 24372302 — intervention group
Group type: COMPARATOR
Intervention: Furosemide administration during LA ablation
Number of subjects: 42
Study 24372302 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedures starting in AF or atrial tachycardia converting to sinus rhythm
Number of subjects: 42
Study 24372302 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedures starting and finishing in sinus rhythm
Number of subjects: 42
Study 22622108 — intervention group
Group type: COMPARATOR
Intervention: Normal blood pressure
Number of subjects: 148
Study 22622108 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 148
Study 22622108 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups during handgrip exercise
Number of subjects: 148
Study 22622108 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension during handgrip exercise
Number of subjects: 148
Study 22622108 — intervention group
Group type: COMPARATOR
Intervention: Normal blood pressure during handgrip exercise
Number of subjects: 148
Study 19754154 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa powder with milk
Number of subjects: 10
Study 19754154 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa powder with water
Number of subjects: 10
Study 19754154 — intervention group
Group type: COMPARATOR
Intervention: Milk without cocoa
Number of subjects: 10